143 related articles for article (PubMed ID: 2704112)
1. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels.
Cunningham GR; Cordero E; Thornby JI
JAMA; 1989 May; 261(17):2525-30. PubMed ID: 2704112
[TBL] [Abstract][Full Text] [Related]
2. Transdermal testosterone therapy in the treatment of male hypogonadism.
Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
[TBL] [Abstract][Full Text] [Related]
3. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
6. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.
Behre HM; von Eckardstein S; Kliesch S; Nieschlag E
Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA
J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
[TBL] [Abstract][Full Text] [Related]
8. Treatment of primary hypogonadism in men by the transdermal administration of testosterone.
Findlay JC; Place V; Snyder PJ
J Clin Endocrinol Metab; 1989 Feb; 68(2):369-73. PubMed ID: 2493029
[TBL] [Abstract][Full Text] [Related]
9. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
Winters SJ; Atkinson L
Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
[TBL] [Abstract][Full Text] [Related]
10. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
Asscheman H; Gooren LJ
Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
[TBL] [Abstract][Full Text] [Related]
11. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males.
Korbonits M; Slawik M; Cullen D; Ross RJ; Stalla G; Schneider H; Reincke M; Bouloux PM; Grossman AB
J Clin Endocrinol Metab; 2004 May; 89(5):2039-43. PubMed ID: 15126518
[TBL] [Abstract][Full Text] [Related]
12. Substitution therapy of hypogonadal men with transdermal testosterone over one year.
Bals-Pratsch M; Langer K; Place VA; Nieschlag E
Acta Endocrinol (Copenh); 1988 May; 118(1):7-13. PubMed ID: 3133918
[TBL] [Abstract][Full Text] [Related]
13. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.
Stuenkel CA; Dudley RE; Yen SS
J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483
[TBL] [Abstract][Full Text] [Related]
14. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.
Kühnert B; Byrne M; Simoni M; Köpcke W; Gerss J; Lemmnitz G; Nieschlag E
Eur J Endocrinol; 2005 Aug; 153(2):317-26. PubMed ID: 16061839
[TBL] [Abstract][Full Text] [Related]
15. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
[TBL] [Abstract][Full Text] [Related]
16. Which testosterone replacement therapy?
Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
[TBL] [Abstract][Full Text] [Related]
17. Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels.
Gooren LJ; Saad F; Haide A; Yassin A
Andrologia; 2008 Oct; 40(5):298-302. PubMed ID: 18811920
[TBL] [Abstract][Full Text] [Related]
18. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
[TBL] [Abstract][Full Text] [Related]
19. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
